35 new R&D projects approved

The projects discussed had requested "medium-sized" investments of NIS 10m. to 30m. each.

By AVI KRAWITZ
May 9, 2006 07:09

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The research committee, headed by Chief Scientist Eli Ofir, has approved 35 new research and development projects with an investment of NIS 278 million, the ministry of Industry, Trade and Labor said Monday. The Chief Scientist will cover NIS 122m. of the total investment from its budget. The approval follows a recent meeting in which the committee considered 47 new R&D projects to fall under its program, requiring a total investment of NIS 510m., the ministry said. The projects discussed had requested "medium-sized" investments of NIS 10m. to 30m. each. Nine of the projects were in the electronics field, six in medical devices, and four in various sectors including chemicals, while 28 communications projects were considered.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS